- Home
- MREO vs HPS Comparison
MREO vs HPS Comparison
Compare MREO & HPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MREO
- HPS
- Stock Information
- Founded
- MREO 2015
- HPS 2003
- Country
- MREO United Kingdom
- HPS United States
- Employees
- MREO N/A
- HPS N/A
- Industry
- MREO Biotechnology: Pharmaceutical Preparations
- HPS Investment Managers
- Sector
- MREO Health Care
- HPS Finance
- Exchange
- MREO Nasdaq
- HPS Nasdaq
- Market Cap
- MREO 438.8M
- HPS 450.7M
- IPO Year
- MREO N/A
- HPS N/A
- Fundamental
- Price
- MREO $2.87
- HPS $14.45
- Analyst Decision
- MREO Strong Buy
- HPS
- Analyst Count
- MREO 5
- HPS 0
- Target Price
- MREO $7.60
- HPS N/A
- AVG Volume (30 Days)
- MREO 1.3M
- HPS 58.4K
- Earning Date
- MREO 08-12-2025
- HPS 01-01-0001
- Dividend Yield
- MREO N/A
- HPS 8.62%
- EPS Growth
- MREO N/A
- HPS N/A
- EPS
- MREO N/A
- HPS N/A
- Revenue
- MREO N/A
- HPS N/A
- Revenue This Year
- MREO N/A
- HPS N/A
- Revenue Next Year
- MREO $52.34
- HPS N/A
- P/E Ratio
- MREO N/A
- HPS N/A
- Revenue Growth
- MREO N/A
- HPS N/A
- 52 Week Low
- MREO $1.58
- HPS $11.79
- 52 Week High
- MREO $5.02
- HPS $15.40
- Technical
- Relative Strength Index (RSI)
- MREO 61.43
- HPS 63.16
- Support Level
- MREO $2.63
- HPS $14.17
- Resistance Level
- MREO $2.85
- HPS $14.20
- Average True Range (ATR)
- MREO 0.16
- HPS 0.14
- MACD
- MREO -0.01
- HPS 0.04
- Stochastic Oscillator
- MREO 79.41
- HPS 95.64
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About HPS John Hancock Preferred Income Fund III Preferred Income Fund III
John Hancock Preferred Income Fund III is a closed-end, diversified management investment company. Its investment objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. It seeks to achieve the objectives by investing a majority of its assets in preferred stocks and other preferred securities, including convertible preferred securities. The portfolio composition of the company consists of the U.S. preferred securities, foreign preferred securities, common stocks, corporate bonds, and the short-term investments.